The EU, which is facing major criticism over its slow rollout of Covid jabs, has even raised the prospect of legal action.
But once it is approved most Australians are expected to receive the AstraZenaca vaccine, which was co-developed with Oxford University.
One EU diplomat said AstraZeneca gave two reasons for the production shortfall, related to materials sourcing and manufacturing problems at a plant in Belgium, but the diplomats said the company had failed to substantiate those claims with evidence.
The move would not, however, cut supplies of the AstraZeneca vaccine because the "vast, vast majority" of their jabs are made in the UK.
"The UK will get what was promised and the European Union will get much less and their explanation is: different supply chains", commented German Christian Democrat MEP Peter Liese.
Tensions have been brewing since last week when the drugmaker announced that production issues would mean it would deliver far fewer doses to the European Union than were promised previously.
An additional meeting was held on Monday evening.
Paroxysms of rage are still convulsing across member states over the European Medical Agency's heel-dragging, which some have attributed to the EU machine's brittle fixation with price over supply.
Ms Kyriakides warned the European Union "will take any action required to protect its citizens and rights", she said in a broadcast address that an "export transparency mechanism" will be installed "as soon as possible".
The EU's vaccine calamity is spiralling into dysfunctional skullduggery worthy of a banana republic.
She also anticipated that the Commission intends to activate an export transparency mechanism for more clarity on transactions and full transparency concerning the export of vaccines from the EU.
Pharmaceutical companies are usually required to deliver ordered doses under quarterly schedules.
UK Minister for COVID Vaccine Deployment Nadhim Zahawi on Tuesday stated that he believes both AstraZeneca and Pfizer will deliver COVID-19 vaccines to the UK and the EU.
European Council President Charles Michel yesterday told Europe 1 that the EU will ensure that pharmaceutical companies respect the contracts they have signed.
The delays in getting vaccines will be make it harder to meet early targets in the EU's goal of vaccinating 70% of its adults by late summer.
Still, the company pushed back in a statement Monday night, saying such accusations are "completely incorrect" and pointing out its use in such populations had been supported by United Kingdom authorities.